Agenus Inc. (NASDAQ:AGEN – Get Rating) – Stock analysts at Jefferies Financial Group dropped their FY2023 earnings estimates for Agenus in a research note issued on Tuesday, March 14th. Jefferies Financial Group analyst K. Shi now expects that the biotechnology company will post earnings per share of ($0.80) for the year, down from their prior forecast of ($0.61). The consensus estimate for Agenus’ current full-year earnings is ($0.87) per share. Jefferies Financial Group also issued estimates for Agenus’ FY2024 earnings at ($0.70) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at ($0.10) EPS.
A number of other brokerages have also commented on AGEN. StockNews.com began coverage on shares of Agenus in a report on Thursday. They set a “sell” rating on the stock. EF Hutton Acquisition Co. I restated a “buy” rating and set a $8.30 price objective on shares of Agenus in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Agenus in a report on Tuesday, February 28th. One analyst has rated the stock with a sell rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.10.
Agenus Stock Performance
Institutional Trading of Agenus
A number of institutional investors have recently bought and sold shares of the business. Trellus Management Company LLC acquired a new position in Agenus during the 3rd quarter worth approximately $1,230,000. Lazard Asset Management LLC increased its position in Agenus by 1,321.3% in the 3rd quarter. Lazard Asset Management LLC now owns 1,153,038 shares of the biotechnology company’s stock valued at $2,363,000 after acquiring an additional 1,071,912 shares during the period. Virtu Financial LLC bought a new stake in shares of Agenus in the 3rd quarter valued at $157,000. Lynch & Associates IN boosted its stake in shares of Agenus by 62.3% in the 4th quarter. Lynch & Associates IN now owns 45,580 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Agenus by 32.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,092,218 shares of the biotechnology company’s stock valued at $2,239,000 after purchasing an additional 266,467 shares during the last quarter. Institutional investors own 53.81% of the company’s stock.
Agenus Company Profile
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.